Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $15.61 in the prior trading day, Oscar Health Inc (NYSE: OSCR) closed at $14.98, down -4.04%. In other words, the price has decreased by -$4.04 from its previous closing price. On the day, 16.06 million shares were traded. OSCR stock price reached its highest trading level at $15.68 during the session, while it also had its lowest trading level at $14.9.
Ratios:
Our goal is to gain a better understanding of OSCR by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
On July 15, 2025, UBS Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $11.
Piper Sandler Downgraded its Overweight to Neutral on July 14, 2025, while the target price for the stock was maintained at $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 20 ’25 when RANMALI BOPITIYA bought 30,000 shares for $18.77 per share.
ALESSANDREA QUANE bought 148,280 shares of OSCR for $2,598,488 on May 16 ’25. On May 12 ’25, another insider, Robinson Elbert O. Jr., who serves as the Director of the company, sold 25,000 shares for $16.43 each. As a result, the insider received 410,750 and left with 64,512 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OSCR now has a Market Capitalization of 3873198848 and an Enterprise Value of 691598144. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.36 while its Price-to-Book (P/B) ratio in mrq is 3.34. Its current Enterprise Value per Revenue stands at 0.064 whereas that against EBITDA is -6.984.
Stock Price History:
The Beta on a monthly basis for OSCR is 1.86, which has changed by -0.1769231 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, OSCR has reached a high of $23.79, while it has fallen to a 52-week low of $11.20. The 50-Day Moving Average of the stock is -5.23%, while the 200-Day Moving Average is calculated to be -0.34%.
Shares Statistics:
The stock has traded on average 24.84M shares per day over the past 3-months and 19606510 shares per day over the last 10 days, according to various share statistics. A total of 222.91M shares are outstanding, with a floating share count of 180.28M. Insiders hold about 29.21% of the company’s shares, while institutions hold 60.82% stake in the company. Shares short for OSCR as of 1753920000 were 60082746 with a Short Ratio of 2.42, compared to 1751241600 on 28587987. Therefore, it implies a Short% of Shares Outstanding of 60082746 and a Short% of Float of 29.950001999999998.
Earnings Estimates
As of right now, 5.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.88 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$1.17 and -$1.91 for the fiscal current year, implying an average EPS of -$1.43. EPS for the following year is -$0.18, with 7.0 analysts recommending between $0.29 and -$0.72.
Revenue Estimates
7 analysts predict $3.08B in revenue for the current quarter. It ranges from a high estimate of $3.14B to a low estimate of $2.96B. As of the current estimate, Oscar Health Inc’s year-ago sales were $2.42BFor the next quarter, 7 analysts are estimating revenue of $3.03B. There is a high estimate of $3.16B for the next quarter, whereas the lowest estimate is $2.81B.
A total of 7 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $12.11B, while the lowest revenue estimate was $11.88B, resulting in an average revenue estimate of $12.04B. In the same quarter a year ago, actual revenue was $9.18BBased on 7 analysts’ estimates, the company’s revenue will be $11.41B in the next fiscal year. The high estimate is $12.69B and the low estimate is $10.9B.
